NCT00482391View on ClinicalTrials.gov

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

lapatinib ditosylate

DRUG

paclitaxel

OTHER

laboratory biomarker analysis

Trial Locations (2)

10021

Memorial Sloan-Kettering Cancer Center, New York

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER